Pfizer and Anumana Ink Multi-Year AI Electrocardiogram Algorithm Deal
Related Articles
Anumana and Pfizer partner for cardiovascular disease detection
Medical Device Network: Health technology company Anumana and Pfizer have signed a multi-year agreement to develop an artificial intelligence electrocardiogram (AI-ECG) algorithm for the early detection of cardiac amyloidosis. Under…December 16, 2022
Anumana, Inc. announced that it has received funding from Boston Scientific Corporation, Matrix Capital Management, Mayo Clinic, Endowment Arm, Matrix Management Corporation, NTT Venture Capital
MarketScreener: Anumana, Inc. announced that it has received a round of funding from new investor, Boston Scientific Corporation on April 24, 2025. The transaction included participation from returning investors, Matrix…April 24, 2025
Could AI and an Apple Watch ECG improve the prognosis for heart failure?
Med City News: Early detection and treatment of heart failure can greatly improve an otherwise poor prognosis. Research from Mayo Clinic suggests artificial intelligence could be used to detect the…May 11, 2022
Mayo-developed AI detects heart condition from Apple Watch ECGs
Modern Healthcare: An artificial-intelligence algorithm developed at Mayo Clinic could identify left ventricular dysfunction—or a weak heart pump—in most patients based on Apple Watch data, researchers shared at a conference…April 30, 2022